Search

Displaying results 361 - 370 of 4359 in total
  1. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated

  2. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.[L10896]. … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid

  3. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.

  4. Drug

    Hyaluronic acid

    go.drugbank.com/drugs/DB08818
    ApprovedInvestigationalVet approved

    Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving...

  5. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.

  6. Drug

    Fluorometholone

    go.drugbank.com/drugs/DB00324
    ApprovedInvestigational

    A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders.

    Mixtures: FML-neo Oph SusProducts: FML Forte Sus 0.25%
  7. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.

  8. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous

  9. Drug

    Dienogest

    go.drugbank.com/drugs/DB09123
    ApprovedInvestigational

    Dienogest is commonly marketed as Visanne, Natazia and Qlaira. … It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself.

  10. Drug

    Zuclopenthixol

    go.drugbank.com/drugs/DB01624
    ApprovedInvestigational

    Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. … Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent.